Profile ng asset

PL2001 · Palatin Technologies, Inc. (PTN)

Indikasyon
mga bihirang sakit sa labis na katabaan na may kaugnayan sa neuroendocrine (hypothalamic obesity, Prader-Willi syndrome, Bardet-Biedl syndrome)
KumpanyaPTNPalatin Technologies, Inc.

Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor (MCR) system. Its product candidates are targeted, receptor-specific therapeutics for the tre…

Nasa kalendaryo

Timeline

Pinakabago muna.

Nob 14, 2026
12:00 PM
PTNPalatin Technologies, Inc.

Ipinapakita ng Palatin ang Preclinical Data sa MC4R Agonist PL2001 sa ObesityWeek 2026

Presentasyon sa kumperensyaPress release ng kumpanya

Iba pa mula sa Palatin Technologies, Inc.

Iba pang gamot at kandidato ng parehong kumpanya na sinusubaybayan sa sektor na ito.

PL2001 · Palatin Technologies, Inc. (PTN) — FDA Timeline at Readiness Checklist | SimianX AI